ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 152 filers reported holding ARRAY BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $5,937,000 | +47.7% | 675,469 | +13.4% | 0.01% | +40.0% |
Q3 2016 | $4,019,000 | +90.7% | 595,435 | +0.6% | 0.01% | +66.7% |
Q2 2016 | $2,107,000 | +46.5% | 591,989 | +21.4% | 0.00% | +50.0% |
Q1 2016 | $1,438,000 | -29.0% | 487,467 | +1.6% | 0.00% | -33.3% |
Q4 2015 | $2,024,000 | -7.5% | 479,611 | -0.0% | 0.00% | 0.0% |
Q3 2015 | $2,187,000 | -37.7% | 479,668 | -1.5% | 0.00% | -25.0% |
Q2 2015 | $3,512,000 | +13.9% | 487,155 | +16.5% | 0.00% | 0.0% |
Q1 2015 | $3,083,000 | +75.3% | 418,251 | +12.5% | 0.00% | +100.0% |
Q4 2014 | $1,759,000 | +30.0% | 371,942 | -1.9% | 0.00% | 0.0% |
Q3 2014 | $1,353,000 | -21.2% | 379,016 | +0.7% | 0.00% | 0.0% |
Q2 2014 | $1,717,000 | +6.5% | 376,494 | +9.7% | 0.00% | 0.0% |
Q1 2014 | $1,612,000 | -4.7% | 343,080 | +1.6% | 0.00% | -33.3% |
Q4 2013 | $1,692,000 | -17.8% | 337,804 | +2.1% | 0.00% | 0.0% |
Q3 2013 | $2,059,000 | +45.9% | 331,004 | +6.5% | 0.00% | 0.0% |
Q2 2013 | $1,411,000 | – | 310,691 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |